Is Gilead Sciences a Good Coronavirus Stock to Buy?
Gilead Sciences (NASDAQ: GILD) has maintained a spot in the forefront of the COVID-19 pandemic. The biotech company first sparked the market's interest when it brought its investigational COVID-19 treatment, remdesivir, rapidly into clinical trials. It solidified its position after the U.S. Food and Drug Administration granted remdesivir emergency use authorization based on encouraging trial data. This authorization isn't the same as approval and can be revoked at any time. That means remdesivir still is involved in clinical testing.
At the same time, the coronavirus vaccine race has heated up, with the U.S. government offering billions of dollars to companies with promising candidates.
Image source: Getty Images.
Source Fool.com
